FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Ethicon $10 Million Settlement Over Surgical Mesh

Johnson & Johnsons Ethicon unit agrees to a $10 million settlement with Kentucky over alleged deceptive marketing practices involving the companys pel...

latest-news-card-1
Human Drugs

Neonatal Neurodevelopmental Safety Study Guide

FDA posts a draft guidance entitled Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development.

latest-news-card-1
Human Drugs

ODAC Panel Backs Proposed Jemperli Studies

An FDA advisory committee votes 8 to 5 that GlaxoSmithKlines proposals for two single-arm clinical trials of its Jemperli (dostarlimab) are sufficient...

latest-news-card-1
FDA General

New AI Tools Will Require FDA Flexibility: Califf

FDA commissioner Robert Califf tells an Alliance for a Stronger FDA fireside chat that while new artificial intelligence advances are quickly becoming...

latest-news-card-1
Medical Devices

EUA for Cepheid Xpert Mpox Test

FDA issues an emergency use authorization for the Cepheid Xpert Mpox test for use in a point-of-care setting for detecting monkeypox.

latest-news-card-1
Human Drugs

Pfizer Expanded Indication for Cibinqo in Adolescents

FDA approves a Pfizer supplemental NDA for Cibinqo (abrocitinib), expanding its indication to include adolescents (12 to 18 years) with refractory, mo...

latest-news-card-1
Federal Register

FDA Withdrawals Emergent Narcan sNDA

Federal Register notice: FDA withdraws the approval of an Emergent Biosolutions supplemental NDA for Narcan (naloxone hydrochloride 2 mg/.1 ml) after ...

latest-news-card-1

HHS Roadmap Outlines FDA Flexibilities Post-Covid

An HHS Covid-19 Public Health Emergency Transition Roadmap outlines FDAs flexibilities and actions that will not be affected after the health emergenc...

latest-news-card-1
Human Drugs

Phathom Gets 2 Complete Response Letters Over Impurity

FDA issues two complete response letters to Phathom Pharmaceuticals one for an NDA for vonoprazan for treating erosive esophagitis, and the other for...

latest-news-card-1

FDA to Explain Post-Health Emergency Effects

Ropes & Gray attorneys explain the impact of the upcoming termination of the Covid-19 public health emergency on FDA guidances and policies.